Michael Burkes Brophy Sells 792 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 792 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $115,663.68. Following the completion of the transaction, the chief financial officer now directly owns 71,869 shares of the company’s stock, valued at approximately $10,495,748.76. The trade was a 1.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Stock Up 3.1 %

Natera stock traded up $4.59 during mid-day trading on Wednesday, hitting $150.87. The company’s stock had a trading volume of 2,162,925 shares, compared to its average volume of 1,349,026. The firm’s 50 day moving average is $162.25 and its 200 day moving average is $149.27. The company has a market cap of $20.40 billion, a PE ratio of -85.72 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. LRI Investments LLC purchased a new stake in shares of Natera during the 4th quarter worth about $29,000. Blue Trust Inc. raised its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares in the last quarter. Finally, Principal Securities Inc. raised its stake in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on NTRA shares. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Morgan Stanley raised their target price on Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Piper Sandler upped their target price on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Finally, Barclays began coverage on Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price for the company. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.